# Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

> **NCT01462773** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Interferon Alfa-2b

## Key facts

- **NCT ID:** NCT01462773
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-10
- **Final completion:** 2013-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462773, "Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01462773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*